Establishment Labs Holdings Inc. (ESTA) Earnings
Establishment Labs Holdings Inc. is expected to report next earnings on August 6, 2026 (in NaN days), with a consensus EPS estimate of $-0.30. ESTA has beaten EPS estimates in 8 of its last 12 reported quarters (average surprise +17.4% over the last four).
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| May 6, 2026 | $-0.35 | $-0.40 | -12.7% | $60M | +4.3% |
| Feb 24, 2026 | $-0.21 | $-0.09 | +58.1% | $65M | +1.3% |
| Nov 5, 2025 | $-0.54 | $-0.38 | +29.6% | $54M | -15.7% |
| Aug 7, 2025 | $-0.54 | $-0.57 | -5.6% | $51M | -2.2% |
| May 7, 2025 | $-0.83 | $-0.70 | +15.7% | $41M | +0.6% |
| Feb 26, 2025 | $-0.64 | $-0.98 | -53.1% | $45M | +0.1% |
| Nov 7, 2024 | $-0.61 | $-0.59 | +3.3% | $40M | -10.0% |
| Feb 28, 2024 | $-0.91 | $-0.79 | +13.2% | $32M | +0.3% |
| Feb 27, 2023 | $-0.68 | $-0.55 | +19.1% | $44M | +1.3% |
| Mar 1, 2022 | $-0.33 | $-0.60 | -81.8% | $35M | +1.3% |
| Jul 29, 2021 | $-0.28 | $-0.22 | +21.4% | $32M | +0.0% |
| May 5, 2021 | $-0.34 | $-0.29 | +14.7% | $30M | -12.8% |
Source: company filings + earnings calendar. For informational purposes only — not investment advice.
Earnings call summary
Q1 FY2026 · May 6, 2026
AI summary of management’s prepared remarks and analyst Q&A. For informational purposes only — not investment advice.
Management highlights
- Q1 2026 was a strong start with revenue growth and adjusted EBITDA positive for third quarter. Gross margin improved by 350 basis points to 70.7%. Refinanced credit facility and expects cash flow positive in second half. Raised full-year revenue guidance. - Establishment Labs is a woman's health company focused on breast aesthetics and reconstruction innovation. Has over 200 patents issued and pending. Motiva implants have low complication rates. - Minimally invasive platform includes Mia and Preserve. Mia is for subtle enhancement, Preserve accommodates primary breast augmentation etc. Launch of minimally invasive techniques can increase market. - In U.S., Motiva continues to expand footprint with over 1,700 accounts. Minimally invasive platform officially launched in March with strong response. Trained over 260 surgeons in U.S. - Outside U.S., business performs well with 15% growth, strong in direct markets and minimally invasive platform. Continued growth expected into 2027 with innovation pipeline including breast reconstruction in U.S., CE mark for ZEN temperature, etc.
Guidance
- Raised full-year revenue guidance to $266.5 to $268.5 million from previous $264 to $266 million. - Expect minimally invasive business to exceed $35 million in 2026, up from prior $30 million guidance. - Expect gross margins in range of 71.2% to 72.2% for full year. - Expect adjusted EBITDA positive in each quarter of 2026 and to achieve cash flow positive in second half of the year.
Segment performance
Q1 2026 had $59.9 million in revenue and adjusted EBITDA of $1.2 million, representing 45% revenue growth over Q1 2025. U.S. business had $19.6 million revenue, up 216% from Q1 2025 and 13.3% quarter-over-quarter. Outside the U.S., 15% growth was delivered. Minimally invasive platform generated $9.1 million in revenue in Q1. U.S. business represents 32.7% of total revenue, with outside the U.S. being the largest revenue contributor.
Risks & headwinds
- Geopolitical landscape impacts business forecasting. - Exposure to Middle East is less than 5% of total revenue, but still need to monitor regional volatility. - Potential impact of macroeconomic environment on demand and costs, such as outward freight surcharges.
Analyst Q&A
Q: Anthony Patron asked about how much new accounts bringing in Motiva as a platform versus Preserve Go Live accounts.
A: Peter Caldini said progress in U.S. is tremendous, driving growth from expanding Motiva business and present day launch of Preserve.
Q: Josh Jennings asked about Preserve not cannibalizing Motiva business and how it's incremental.
A: Peter Caldini said Preserve and Mia operate complimentary, with MIA in premium segment and Preserve more day-to-day, and minimally invasive has opportunity to drive category growth.
Q: Sam Eber asked about Preserve becoming standard of care and why it's only done with Motiva.
A: Peter Caldini said Preserve has patient benefits and innovation with unique implants makes it beneficial.
Q: Mason Carrico asked if Preserve launch accelerated onboarding of new accounts.
A: Peter Caldini said outside U.S. Preserve brought new accounts, and in U.S. it has potential to drive account acquisition.
Q: Caitlin Roberts asked about Preserve and MIA split and ERGO II timeline.
A: Peter Caldini said bulk driven by Preserve, and ERGO II approval not a significant driver until around 2028.
Q: Joanne Wage asked about macroeconomic environment impact.
A: Peter Caldini and Sandra Harris said Middle East is small part of business, and monitored freight costs and silicone costs.
Q: Alan Gong asked about guidance and cadence.
A: Peter Caldini said orders specific to U.S., strong momentum into Q2, and Middle East has demand.
Q: Matt Baylor asked about silicone supply cost increases.
A: Peter Caldini said good relationship with Nusil, productive conversations, and intent to have long-term agreement.
Q: Mike Matson asked about refinancing impact on interest expense.
A: Sandra Harris said new debt agreement has lower interest rate and pick feature, net-net slightly up.
Q: Anthony Patron asked about gross margin guidance.
A: Sandra Harris said gross margin improvement from U.S. growth, minimally invasive launch, and no assumptions on FDA clearance for reconstruction yet